The feasibility study of modified XP (+ trastuzumab) for the patients who underwent gastrectomy for Stage IV gastric cancer: EXPRESS-GC study

The feasibility study of modified XP (+ trastuzumab) for the patients who underwent gastrectomy for Stage IV gastric cancer: EXPRESS-GC study - The feasibility study of modified XP (+ trastuzumab) for the patients who underwent gastrectomy for Stage IV gastric cancer: EXPRESS-GC study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013840

Enrollment

Registered

2014-05-01

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Capecitabine/CDDP(+Trasutuzumab)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) StageIV gastric cancer histologically proven to be adenocarcinoma (2) Undergoing gastrectomy (3) Age : 20 years old and more (4) Performance status (ECOG) 0-1 (5) Oral drug administration during 8 postoperative weeks (6) Adequate organ functions (7) Life expectancy : 12 weeks and more (8) Ability to understand and willingness to sign a written informed consent before study entry (9) LVEF equal or more than 50% when trasutuzumab administered

Exclusion criteria

Exclusion criteria: (1) Second primary malignancy except in situ carcinoma or prior malignancy treated within 5 years (2) Serious illness (3) Severe infectious disease (4) Active gastrointestinal bleeding (5) Severe diarreha (6) Past history of severe hypersensitivity to drugs (7) Suspicious past history of DPD deficiency (8) Contraindication for trastuzumab, capecitabine and cisplatin (9) Requirement of continuation for phenytoin and warfarin (10) Pregnant or lactating woman (11) Women of child bearing potential not using a contraceptive method. Sexually active fertile men not using effective birth control. (12) Psychological illness (13) Any patients judged by the investigator to be unfit to participate in the study

Design outcomes

Primary

Measure	Time frame
completion rates of 4 courses treatment of Capecitabine/CDDP(+Trasutuzumab)	—

Countries

Japan

Contacts

Public ContactDaisuke Kobayashi

Nagoya University, Graduate School of Medicine Gastroenterorogical Surgery

kobadai@med.nagoya-u.ac.jp052-744-2249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026